Transmedics Group ( (TMDX) ) has released its Q3 earnings. Here is a breakdown of the information Transmedics Group presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, aiming to improve the availability and quality of organs for patients with end-stage heart, lung, and liver failure.
In the third quarter of 2025, TransMedics reported a significant increase in its financial performance, with total revenue reaching $143.8 million, marking a 32% rise compared to the same period in 2024. The company also announced a strategic collaboration with Mercedes-Benz Group AG to enhance organ transportation in Italy.
Key financial highlights include a net income of $24.3 million, or $0.66 per diluted share, and a gross margin improvement to 59%. The increase in revenue was primarily driven by the expanded use of the Organ Care System (OCS) and the National OCS Program (NOP), supported by the company’s growing aviation fleet. Operating expenses rose to $61.3 million due to increased investments in research and development.
Looking ahead, TransMedics has raised its full-year 2025 revenue guidance to between $595 million and $605 million, reflecting a 36% growth at the midpoint compared to the previous year. The company remains focused on ending the year strongly and is well-positioned for continued growth in 2026, leveraging its unique technology and strategic partnerships.